Clinical Trial Data, Pharmacovigilance Records and Patient Registries Are All Personal Data Under DPDPA
The DPDPA does not create a separate category for health data. But pharmaceutical companies process some of the most sensitive personal data in India — and face unique compliance challenges at the intersection of data protection and health regulation.
Global pharmaceutical companies operating in India process personal data across the entire product lifecycle — from clinical trial participant data and pharmacovigilance reports to prescriber information, patient support programme records, and commercial analytics. Every data point relating to an identified or identifiable natural person is personal data under Section 2(t) of the DPDPA.
The absence of a "sensitive personal data" category in DPDPA (unlike the 2019 Bill and unlike GDPR Article 9) does not reduce the compliance burden for pharmaceutical companies. The general obligations — consent, notice, security safeguards, breach notification, data retention — apply with full force. And sectoral regulations from CDSCO, ICMR, and the National Medical Commission add additional layers.
Clinical Trial Data Under DPDPA
Clinical trial participant data is personal data. The legal basis for processing must be established for each phase of the trial. Consent under the Clinical Trials Rules, 2019 (CDSCO) is not automatically DPDPA-compliant consent. The DPDPA requires a separate notice (Section 5) and separate consent (Section 6) for any data processing beyond the clinical trial protocol. Data shared with the sponsor's headquarters outside India must comply with Section 16.
Pharmacovigilance and Adverse Event Reporting
Pharmacovigilance processing may qualify as a legitimate use under Section 7(a) — compliance with law — to the extent mandated by CDSCO regulations. However, the Section 5 notice obligation still applies. Patients whose adverse event data is reported must be informed of the processing. And cross-border transfer of pharmacovigilance data to the global safety database must comply with Section 16.
Key DPDPA Obligations
| Obligation | Section / Rule | Description |
|---|---|---|
| Clinical trial consent alignment | Section 6 + CDSCO Rules | DPDPA consent layered on CDSCO informed consent for data processing beyond trial protocol |
| Pharmacovigilance notice | Section 5 + Section 7(a) | Notice to patients whose adverse event data is processed, even under legitimate use |
| HCP data processing | Section 6 | Consent from healthcare professionals whose prescribing data is processed for commercial analytics |
| Cross-border clinical data | Section 16 | Trial data shared with global sponsor headquarters mapped against restricted jurisdictions |
| Patient registry retention | Section 8(7) | Purpose-mapped retention schedules for patient support programme data |
| Vendor governance | Section 8(2) | DPAs with CROs, pharmacovigilance service providers, and medical information vendors |
Request a Pharmaceutical DPDPA Compliance Architecture Review
A confidential review of your India pharmaceutical operations — clinical trial data flows, pharmacovigilance compliance, patient registry governance, and cross-border data transfer architecture mapped against DPDPA.
Request a Confidential Briefing
Our data privacy counsel will reach out within one working day.
Frequently Asked Questions
Is health data treated differently under DPDPA?
No. Unlike GDPR (Article 9) and the 2019 Personal Data Protection Bill, the DPDPA does not create a separate category for sensitive personal data or health data. All personal data is subject to the same obligations. However, pharmaceutical companies should implement enhanced security safeguards for health data under Section 8(4) to satisfy the reasonableness standard.
Does clinical trial consent satisfy DPDPA consent requirements?
Not automatically. CDSCO informed consent covers participation in the trial. DPDPA consent under Section 6 covers processing of personal data. If the pharmaceutical company processes trial participant data for purposes beyond the trial protocol — such as future research, publication, or internal analytics — separate DPDPA consent is required for each additional purpose.